179: Unrelated donor umbilical cord blood transplant following intrauterine transfusions for treatment of alpha thalassemia major  by Rivers, A.E. et al.
preparative regimen (IV busulfan); from day 0 to 100 patients
were admitted for a median of 11 days (0 – 25). We conclude
that in children, using ECP as part of RIC and GVHD preven-
tion is well tolerated and feasible, time to engraftment is ac-
ceptable, and complications are minimal as evidenced by short
inpatient stays. However, immune suppression appears to be
excessive given the rates of CMV reactivation and declining
chimerism of two patients while on ECP. ECP appears to be
effective in preventing aGVHD, as the only patients who de-
veloped aGVHD were those requiring immune modulation.
Table #1
Daignosis Donor
Chimerism
> 50%
(days)
Chimerism
> 95%
(days) aGVHD cGVHD
Disease
Status
1 CML Matched
Sibling
13 29 None None NED
following
DLI &
Imatinib
for
rising
BCR/ABL,
day
446
2 SAA Matched
Sibling
8 26 None Extensive NED,
day 390
3 CML Matched
Sibling
26 63
(Following
DLI)*
Grade 3 Extensive NED,
day 340
4 SAA Mismatched
Related
12 81
(Following
removal of
immune
supression)*
Grade 3 Limited NED,
day 284
5 Relapsed
ALL (CR2)
Matched
Sibling
12 28 None None Relapse,
day 100
6 Recurrent
HD (CR3)
MUD 20 33 None None Relapse,
day
100,
died of
PD
7 SAA Matched
Sibling
7 12 None None NED,
day 187
8 Recurrent
HD (CR2)
Matched
Sibling
28 47 None None NED,
day 124
9 SAA MUD No
engraftment
No
engraftment
None N/A Died
day
37,
fungal
infection
10 Peripheral
T-cell
Lymphoma
MUD 12 12 None N/A NED,
day 33
*Interventions due to falling chimerism
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COMBINED TACROLIMUS (FK-506) AND MYCOPHENOLATE MOFETIL
(MMF) FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS IN
CHILDREN UNDERGOING CORD BLOOD TRANSPLANTATION (CBT)
Soni, S.1, Hente, M.2, Breslin, N.2, Bertolone, S.2, Cheerva, A.2 1Co-
lumbus Children’s Hospital, Columbus, OH; 2Kosair Children’s Hospi-
tal, Louisville, KY.
Background: Effectiveness of FK-506 and MMF combination as
prophylaxis for GVHD is still under investigation. We studied the
feasibility and effectiveness of this regimen in preventing GVHD
in children undergoing matched unrelated donor (MUD) CBT to
avoid methotrexate and methylprednisone toxicity.
Patients and Methods: Between 5/1/04-9/1/06, 11 children
undergoing MUD CBT have received FK-506 and MMF combi-
nation as prophylaxis for GVHD. Thymoglobulin (Rabbit ATG,
2.5-5mg/kg total) was used as part of the conditioning regimen.
Both myeloablative (n9) and non-myeloablative (n2) prepara-
tive regimens were used and majority of the children (n7) have
received one antigen mismatch (Class I/II-antigen disparate) CBT.
FK-506, 0.015mg/kg IV every 12 hours (infused over 6 hours) was
started on day-2 (trough level maintained 5-15 ng/ml),rather than
as a continuous infusion. MMF was started on day 1 at 15mg/kg
/dose IV q 8-12 hours and stopped on day 30, if there were no
signs of GVHD. Both were converted to PO formulation at the
time of discharge. MMF levels (active MPA) were monitored
weekly.
Results: The regimen was well tolerated. Only major side-effect
noted was hypertension in the ﬁrst 2 patients, which was controlled
with prophylactic anti-hypertensive use in subsequent patients.
Tremors occurred in 2 patients and responded to MMF taper. No
major neuro- or nephrotoxicity was noted. All children have en-
grafted (median16 days). No patient has developed Grade II
GVHD (Glucksberg staging criteria). 6/11 patients (54.5%) had
developed Grade I/II GVHD, limited only to skin and gut (1 pt.)
that was steroid-responsive. Only 1/6 patients continued to have
limited chronic GVHD of the skin (median follow-up: 255days ;
range: 62-725 days). Immune-reconstitution was not delayed.
MMF levels ranged from 0.5-5.7 mcg/ml. No correlation was
seen between the MMF levels and the incidence of GVHD in this
study.
Conclusion: FK-506/MMF combination is well tolerated, does
not affect engraftment kinetics or immune-reconstitution and is
efﬁcacious in preventing GVHD in CBT.
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HHV-6 INFECTION FOLLOWING CAMPATH1H BASED REDUCED INTEN-
SITY CONDITIONING (RIC) REGIMEN IN PEDIATRIC PATIENTS UNDER-
GOING SCT FOR NON-MALIGNANT DISORDERS
Soni, S.1, Barnes, Y.2, Hayashi, R.2, Manna, P.3, Shenoy, S.2 1Colum-
bus Children’s Hospital, Columbus, OH; 2Wahington University School
of Medicine, St. Louis, MO; 3Dept. of Molecular Diagnostic Research,
Viracor Laboratories, Lee’s Summit, MO.
Background: Human Herpes Virus 6 (HHV-6) infections have
been recently recognized as complications of SCT in young pa-
tients. Limited information is available on patterns and impact of
HHV-6 infection following RIC transplants using increased im-
munosuppression. We describe our multi-institutional experience
with HHV-6 infections during SCT following a Campath IH
based RIC regimen.
Patients and Methods: 12 patients underwent SCT for non-
malignant disorders and received Campath 1H (33mg/48mg, day
-21 and day-19); Fludarabine (150mg/m2,day -8 to -4) and Mel-
phalan (70 or 140mg/m2, day-3) prior to stem cell infusion (BM/
PBSC/CB) from related or unrelated donors. Two patients had
also received Thiotepa (10mg/kg on day-2). Acyclovir was used for
viral prophylaxis. Patients were tested for HHV-6 pre-transplan-
tation by a PCR based assay. Patients were monitored by HHV-6
PCR if they had fever, delayed engraftment/myelo-suppression,
rash or malaise. Serial quantitative real-time PCRs (viral load) data
was collected in some of these patients (Viracor Laboratories,
Missouri) to gauge response to treatment.
Results: All 12 patients undergoing SCT were negative for
HHV-6 by PCR pre-transplant. 7 patients (58.3%) had HHV-6
detected during the course of their SCT. Infections occurred
during the ﬁrst month (n4), second month (n1), at 4 months
(n1) and at 6months (n1) post-SCT. Common symptoms en-
countered were fever, rash and pancytopenia/delayed engraftment.
No case of pneumonitis or encephalitis was seen. HHV-6 infection
responded rapidly to Foscarnet or Gangcyclovir with decrease in
viral load and was associated with no deaths. No HHV-6 infections
were seen after immune-reconstitution (6 months).
Conclusions: Infection with HHV-6 infection is more frequent
following Campath based regimen. Most of the infections occur
within the ﬁrst 4 weeks and may delay engraftment; but late
infections are also common due to intense immunosuppression.
Therefore, close monitoring and early treatment is advocated in
pediatric patients receiving Campath 1H.
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UNRELATED DONOR UMBILICAL CORD BLOOD TRANSPLANT FOLLOW-
ING INTRAUTERINE TRANSFUSIONS FOR TREATMENT OF ALPHA
THALASSEMIA MAJOR
Rivers, A.E.1, Richard, D.1, Harris, N.1, Chui, D.H.K.2,
Slayton, W.B.1, Staba, S.L.1 1University of Florida, Gainesville, FL;
2Hemoglobin Diagnostic Reference Laboratory, Boston, MA.
Homozygous 0-thalassemia (deletion of all 4 -globin genes)
results in Hb Bart’s (4 tetramers). Almost universally fetal death
from hydrops occurs prior to diagnosis, therefore not allowing the
opportunity for treatment. Advancement of maternal-fetal medi-
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cine and ultrasound has led to the possibility of in utero diagnosis
and treatment with intrauterine transfusions. Rare cases of prema-
ture infants surviving and undergoing chronic transfusion therapy
have been reported. Hematopoietic stem cell transplant (HSCT)
has become increasingly used to cure beta thalassemia, and pro-
vides the potential to cure 0thalassemia. To date, 3 reported cases
of 0thalassemia have been treated with HSCT. Two children
underwent matched sibling HSCT at 20 and 21 months of age and
one a 5/6 HLA matched sibling umbilical cord blood transplant
(UCBT). One child had received intrauterine transfusions. We
report a case of an infant with 0thalassemia successfully treated
with intrauterine transfusions followed by unrelated donor UCBT.
The mother, of Cambodian descent, noticed decreased fetal move-
ment at 23 weeks gestation and ultrasound revealed hydrops fetalis.
Based on nationality and previous fetal loss, the suspicion of
0thalassemia was raised. UCB sampling revealed a hypochromic,
microcytic anemia with target cells. The Hgb electrophoresis dem-
onstrated Hgb Barts and Portland. Subsequent genotyping con-
ﬁrmed deletion of all 4 -globin genes. The patient received 3
intrauterine transfusions prior to delivery at 32 weeks. The hospital
course was relatively uneventful and included PRBC transfusions.
After discharge, he received 3 transfusions. Following informed
consent, at 6 months of age, he was conditioned for transplant with
busulfan, cytoan and ATG. Lacking an HLA matched sibling, he
received a 5/6 HLA matched unrelated donor UCB unit delivering
11.8  107 nucleated cells/kg. Neutrophil engraftment
(ANC500) was achieved on day  15. FK506 and methotrexate
5mg/m2 on days 1, 3 and 6 was utilized for GVHD prophylaxis.
His course was complicated by moderate venoocclusive disease,
small subdural hemorrhage, and viremia. He has not had any
evidence of graft versus host disease. Initial chimerism (STRs)
showed approximately 63% donor derived cells, since increasing
with 100% T-cell engraftment. He clinically is doing well post
transplant. This case demonstrates that intrauterine transfusion
followed by unrelated donor UCBT is feasible for the treatment of
0thalassemia.
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CHRONIC GRAFT-VERSUS HOST DISEASE (GVHD) IN CHILDREN WITH
MUCOPOLYSACHARIDOSES (MPS) TWO YEARS AFTER UNRELATED DO-
NOR UMBILICAL CORD BLOOD TRANSPLANTATION (UCBT)
Szabolcs, P.1, Martin, P.L.1, Parikh, S.1, Prasad, V.K.1, Vinesett, R.1,
Escolar, M.L.2, Kurtzberg, J.1 1Duke University Pediatric BMT Pro-
gram, Durham, NC; 2Center for Development and Learning, UNC-
CH, Chapel Hill, NC.
MPS are a group of metabolic storage diseases caused by lyso-
somal enzyme deﬁciencies resulting in the accumulation of glycos-
aminoglycans in multiple organs. Unrelated Cord Blood Trans-
plantion (UCBT) can prevent progression of organ dysfunction in
MPS. UCBT can slow or halt cognitive deterioration in early cases
of MPS II and III and improves cognitive outcome for MPS I.
However, even after full donor engraftment quality of life and
neurocognitive outcome can be adversely affected by post-trans-
plant complications such as chronic GVHD and its treatments. In
this retrospective analysis, we sought to determine how many
children receive systemic immunosuppressive (IS) drugs at the 2
year time point at the single largest center performing UCBT for
MPS. Over 90% of Duke patients with MPS are out of state and
are followed locally after 6-9 months. However, even these patients
return to Duke for yearly visits. Receiving systemic IS drugs was
chosen as a surrogate marker of active chrGvHD. Patients between
ages 1 and 50 months (median 18 months) underwent UCBT for
treatment of MPS I (Hurler), MPS II (Hunter), and MPSIII
(Sanﬁlippo Syndrome). Preparative regimen consisted of busul-
fan  cyclophosphamide with equine ATG as previously described
(COBLT study). Cyclosporine A and SoluMedrol were used as
GvHD prophylaxis. Systemic IS is expected to be tapered starting
between 6 and 12 months after UCBT. In the absence of active
GVHD, patients are weaned off all IS between 12-16 months
post-UCBT. Fourty seven (47) MPS patients were transplanted
between 1995 and September 2004, (MPSI n33, MPSII n2,
MPS IIIA n8 , MPS IIIB n4) Thirty three (33) out of the 47
were alive 2 years post-UCBT (70%). Ten out of the thirty three
survivors (30%) were receiving systemic IS drug at the 2 year visit
with the recommendation to continue. Five of these had limited
skin GvHD while ﬁve had skin plus other organ involvement
(cytopenias in 2 and GI tract in another 3). One received CellCept
only and two were on FK506 alone. Three children received 2
agents (FK506 and Prednisone). Four children received three drug
combination (FK506, low dose Prednisone, and Daclizumab).
Mean CD4 T cells were 1400/mm3  950. One patient died
before the 3 year f/up with compliactions related to GVHD, while
all other patients are alive. Taken together, a subset of MPS
patients experience prolonged exposure to IS drugs that may
hinder neurocognitive outcome after UCBT. Risk factors are cur-
rently analyzed.
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KINETICS OF ENGRAFTMENT FOLLOWING DUAL UNRELATED CORD
BLOOD TRANSPLANTATION WITH REDUCED INTENSITY CONDITION-
ING
Tan, P.-L.1, Villegas, M.S.1, Chan, Y.-H.3, Yeoh, E.-J.2, Quah, T.-C.2
1Paediatrics, National University Hospital, Singapore, Singapore; 2Pae-
diatrics, Yong Loo Lin School of Medicine, National University of Sin-
gapore, Singapore, Singapore; 3Biostatistics Unit, Yong Loo Lin School of
Medicine, National University of Singapore, Singapore, Singapore.
Reduced intensity conditioning (RIC) is a safer alternative to
conventional myeloablative conditioning for patients at high risk of
transplant-related morbidity/ mortality. For these patients lacking
adult donors, unrelated donor cord blood transplant (CBT) is a
feasible alternative. However, CBT with RIC may pose unaccept-
able risks of graft rejection, hence compromising outcome. To
enhance engraftment, dual donors CBTs with RIC have been
performed with promising results in pediatric patients in our cen-
tre. Little is known on the kinetics of engraftment and the deﬁning
factor/s determining the ﬁnal engrafted unit in this setting. We
analyzed these variables in 8 patients (6 with acute lymphoblastic
leukemia (ALL), 1 with hemophagolymphohistiocytosis (HLH), 1
with CD40 ligand deﬁciency) who received mismatched, dual un-
related CBT after RIC with ﬂudarabine, cyclophosphamide, low
dose TBI  low dose ATG between 2004 - 2006. All except the
patient with HLH engrafted. In 6 evaluable patients, mixed chi-
merism was noted in 50% of the patients early after transplant
(D14). Analyzed separately, all patients with ALL achieved 
90% donor chimera by D34 after transplant. All but 1 patient
with ALL (83%) are in continuous complete remission to date.
The patient with CD 40 ligand achieved complete donor chimera
on D125 after transplant. Contrary to reports of prolong mixed
chimera states after RIC, which may predispose to graft failure and
relapse, the kinetics of engraftment in our patients with ALL was
quick and robust. Early engraftment kinetics also revealed domi-
nance of one of the two units in majority of these patients.
Amongst other factors, the ﬁnal engrafted cord units have higher
post-thaw cell doses. These data demonstrated that sustained, full
donor chimera can be achieved early after RIC transplants with
dual CBT in pediatric patients with ALL without compromising
survival and relapse risks.
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MOBILIZATION OF PML-RARA NEGATIVE PERIPHERAL BLOOD STEM
CELLS AND AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANS-
PLANT IN PEDIATRIC PATIENTS WITH RELAPSED ACUTE PROMYELO-
CYTIC LEUKEMIA
Termuhlen, A.M.1, Klopfenstein, K.J.2, Boyer, M.1, Rosselet, R.M.1,
Altura, R.3, Olshefski, R.1, Yeager, N.D.1, Gross, T.G.1 1Department of
Pediatrics, Columbus Children’s Hospital, The Ohio State University
College of Medicine and Public Health, Columbus, OH; 2Department of
Pediatrics, East Tennessee State University, Johnson City, TN; 3Depart-
ment of Pediatrics, Columbus Children’s Research Institute, The Ohio
State University College of Medicine and Public Health, Columbus, OH.
Autologous stem cell transplant has failed to demonstrate beneﬁt
in most children with relapsed acute myelogenous leukemia. Ten
to twenty percent of children with acute promyelocytic leukemia
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